AGBL2

Summary

AGBL2 (AGBL carboxypeptidase 2, HGNC:26296) is a protein-coding gene on chromosome 11p11.2, encoding Cytosolic carboxypeptidase 2 (Q5U5Z8). Metallocarboxypeptidase that mediates deglutamylation of tubulin and non-tubulin target proteins.

Predicted to enable metallocarboxypeptidase activity and tubulin binding activity. Predicted to be involved in protein side chain deglutamylation. Located in centriole and ciliary basal body.

Source: NCBI Gene 79841 — RefSeq curated summary.

At a glance

• Gene–disease (curated): epilepsy (Limited, GenCC)
• GWAS associations: 26
• Clinical variants (ClinVar): 126 total — 1 pathogenic
• Druggable target: yes
• MANE Select transcript: NM_024783

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:26296
Approved symbol	AGBL2
Name	AGBL carboxypeptidase 2
Location	11p11.2
Locus type	gene with protein product
Status	Approved
Aliases	FLJ23598, CCP2
Ensembl gene	ENSG00000165923
Ensembl biotype	protein_coding
OMIM	617345
Entrez	79841

Gene structure

Transcript identifiers

Ensembl transcripts: 13 — 6 protein_coding, 4 protein_coding_CDS_not_defined, 2 nonsense_mediated_decay, 1 retained_intron

ENST00000425363, ENST00000525123, ENST00000526331, ENST00000528244, ENST00000528609, ENST00000528632, ENST00000529154, ENST00000529712, ENST00000530577, ENST00000530969, ENST00000531835, ENST00000532595, ENST00000532835

RefSeq mRNA: 1 — MANE Select: NM_024783 NM_024783

CCDS: CCDS7944

Canonical transcript exons

ENST00000525123 — 19 exons

Exon	Start	End
ENSE00001339120	47705521	47705634
ENSE00002186014	47715175	47715369
ENSE00003466841	47704543	47704728
ENSE00003473980	47685893	47686049
ENSE00003504527	47692103	47692256
ENSE00003510515	47710377	47710511
ENSE00003512747	47714618	47714750
ENSE00003531171	47681969	47682095
ENSE00003549893	47699446	47699553
ENSE00003618609	47690076	47690858
ENSE00003629282	47659591	47660346
ENSE00003629344	47667571	47667696
ENSE00003652539	47679973	47680073
ENSE00003660188	47668841	47668907
ENSE00003686912	47677271	47677401
ENSE00003692199	47666956	47667063
ENSE00003693505	47663026	47663112
ENSE00003787971	47714284	47714347
ENSE00003790182	47705864	47705917

Expression profiles

Bgee: expression breadth ubiquitous, 133 present calls, max score 98.82.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 2.5442 / max 70.3693, expressed in 996 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
119665	2.5442	996

Top tissues by expression

134 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right uterine tube	UBERON:0001302	98.82	gold quality
left testis	UBERON:0004533	92.23	gold quality
right testis	UBERON:0004534	91.85	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	91.48	gold quality
testis	UBERON:0000473	91.33	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	84.74	gold quality
fallopian tube	UBERON:0003889	83.19	gold quality
right lobe of liver	UBERON:0001114	80.30	gold quality
right adrenal gland	UBERON:0001233	76.48	gold quality
pituitary gland	UBERON:0000007	76.35	gold quality
liver	UBERON:0002107	76.12	gold quality
right adrenal gland cortex	UBERON:0035827	75.54	gold quality
adenohypophysis	UBERON:0002196	75.50	gold quality
cerebellar hemisphere	UBERON:0002245	75.19	gold quality
cerebellar cortex	UBERON:0002129	75.08	gold quality
right hemisphere of cerebellum	UBERON:0014890	74.99	gold quality
cerebellum	UBERON:0002037	74.95	gold quality
endometrium	UBERON:0001295	74.82	gold quality
cortex of kidney	UBERON:0001225	74.79	gold quality
metanephros cortex	UBERON:0010533	74.47	gold quality
adrenal tissue	UBERON:0018303	74.39	gold quality
left adrenal gland cortex	UBERON:0035825	74.31	gold quality
left adrenal gland	UBERON:0001234	73.87	gold quality
mucosa of transverse colon	UBERON:0004991	73.30	gold quality
left uterine tube	UBERON:0001303	73.13	gold quality
granulocyte	CL:0000094	72.86	gold quality
left ovary	UBERON:0002119	72.84	gold quality
right lung	UBERON:0002167	72.83	gold quality
adrenal gland	UBERON:0002369	72.67	gold quality
duodenum	UBERON:0002114	72.17	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	9.99

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

48 targeting AGBL2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-6758-5P	100.00	66.21	1470
HSA-MIR-6856-5P	100.00	65.47	1298
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-4500	99.99	72.72	2367
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-4803	99.98	71.99	3117
HSA-MIR-4482-3P	99.98	72.50	3147
HSA-LET-7I-5P	99.98	72.37	1788
HSA-MIR-4775	99.98	75.00	6394
HSA-LET-7A-5P	99.98	72.29	1790
HSA-LET-7B-5P	99.98	72.31	1790
HSA-LET-7C-5P	99.98	72.29	1790
HSA-LET-7E-5P	99.98	72.29	1790
HSA-LET-7F-5P	99.98	72.56	1784
HSA-LET-7G-5P	99.98	72.37	1784
HSA-MIR-98-5P	99.98	72.33	1787
HSA-MIR-302C-5P	99.97	72.56	3642
HSA-MIR-507	99.97	70.11	1915
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-557	99.96	70.01	1640
HSA-MIR-302E	99.96	70.74	2669
HSA-MIR-4697-3P	99.89	67.09	1123
HSA-MIR-202-3P	99.84	71.41	1290
HSA-MIR-148A-3P	99.74	73.77	1700
HSA-MIR-148B-3P	99.74	73.75	1700
HSA-MIR-152-3P	99.74	73.75	1703
HSA-MIR-4422	99.72	72.07	2908
HSA-MIR-466	99.67	70.85	2863
HSA-MIR-1303	99.65	69.77	1662

Literature-anchored findings (GeneRIF, showing 5)

• RARRES1, its interacting partners AGBL2, Eg5/KIF11, another EEY-bearing protein (EB1), and the microtubule tyrosination cycle are important in tumorigenesis. (PMID:21303978)
• High AGBL2 expression is associated with breast cancer. (PMID:24884516)
• Suggest role for AGBL2 in cell proliferation and chemotherapy resistance in gastric cancer. (PMID:25916089)
• Findings suggest that ATP/GTP binding protein like 2 (AGBL2) plays a critical oncogenic role in the pathogenesis of hepatocellular carcinoma (HCC) through modulation on immunity-related GTPase family, M protein (IRGM)-regulated autophagy and aurora kinase A (Aurora A) activity. (PMID:29126912)
• Expression of RARRES1 and AGBL2 and progression of conventional renal cell carcinoma. (PMID:32307444)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	agbl2	ENSDARG00000079983
mus_musculus	Agbl2	ENSMUSG00000040812
rattus_norvegicus	Agbl2	ENSRNOG00000008467

Paralogs (5): AGBL5 (ENSG00000084693), AGTPBP1 (ENSG00000135049), AGBL3 (ENSG00000146856), AGBL4 (ENSG00000186094), AGBL1 (ENSG00000273540)

Protein

Protein identifiers

Cytosolic carboxypeptidase 2 — Q5U5Z8 (reviewed: Q5U5Z8)

Alternative names: ATP/GTP-binding protein-like 2, Protein deglutamylase CCP2

All UniProt accessions (9): A0A140VKH9, E9PI49, E9PJH3, E9PR59, E9PRJ1, E9PS54, F6U0I4, J9JIH1, Q5U5Z8

UniProt curated annotations — full annotation on UniProt →

Function. Metallocarboxypeptidase that mediates deglutamylation of tubulin and non-tubulin target proteins. Catalyzes the removal of polyglutamate side chains present on the gamma-carboxyl group of glutamate residues within the C-terminal tail of tubulin protein. Specifically cleaves tubulin long-side-chains, while it is not able to remove the branching point glutamate. Also catalyzes the removal of polyglutamate residues from the carboxy-terminus of non-tubulin proteins such as MYLK.

Subunit / interactions. Interacts with RARRES1, KIF11 AND MAPRE1.

Subcellular location. Cytoplasm. Cytosol. Cytoskeleton. Microtubule organizing center. Centrosome. Centriole. Cilium basal body.

Activity regulation. Inhibited by RARRES1.

Cofactor. Binds 1 zinc ion per subunit.

Similarity. Belongs to the peptidase M14 family.

Isoforms (3)

UniProt ID	Names	Canonical?
Q5U5Z8-1	1	yes
Q5U5Z8-2	2
Q5U5Z8-3	3

RefSeq proteins (1): NP_079059* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000834	Peptidase_M14	Domain
IPR040626	Pepdidase_M14_N	Domain
IPR050821	Cytosolic_carboxypeptidase	Family

Pfam: PF00246, PF18027

Catalyzed reactions (Rhea), 1 shown:

• (L-glutamyl)(n+1)-gamma-L-glutamyl-L-glutamyl-[protein] + H2O = (L-glutamyl)(n)-gamma-L-glutamyl-L-glutamyl-[protein] + L-glutamate (RHEA:60004)

UniProt features (17 total): sequence variant 5, binding site 3, splice variant 2, region of interest 2, compositionally biased region 2, chain 1, domain 1, active site 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q5U5Z8-F1	72.22	0.49

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 630 (proton donor/acceptor)

Ligand- & substrate-binding residues (3): 462; 465; 558

Function

Pathways and Gene Ontology

Reactome pathways

3 pathways

ID	Pathway
R-HSA-8955332	Carboxyterminal post-translational modifications of tubulin
R-HSA-392499	Metabolism of proteins
R-HSA-597592	Post-translational protein modification

MSigDB gene sets: 69 (showing top): GOMF_METALLOPEPTIDASE_ACTIVITY, TGACCTY_ERR1_Q2, GOCC_MICROTUBULE_ORGANIZING_CENTER, SENGUPTA_NASOPHARYNGEAL_CARCINOMA_DN, OCT1_06, GOBP_PEPTIDYL_GLUTAMIC_ACID_MODIFICATION, ZHOU_INFLAMMATORY_RESPONSE_LIVE_DN, PTF1BETA_Q6, GOCC_CENTRIOLE, GOBP_PROTEOLYSIS, RFX1_01, IRF2_01, GOCC_CILIUM, GOCC_CILIARY_BASAL_BODY, GOMF_CARBOXYPEPTIDASE_ACTIVITY

GO Biological Process (2): proteolysis (GO:0006508), protein side chain deglutamylation (GO:0035610)

GO Molecular Function (9): metallocarboxypeptidase activity (GO:0004181), zinc ion binding (GO:0008270), tubulin binding (GO:0015631), carboxypeptidase activity (GO:0004180), protein binding (GO:0005515), peptidase activity (GO:0008233), metallopeptidase activity (GO:0008237), hydrolase activity (GO:0016787), metal ion binding (GO:0046872)

GO Cellular Component (7): cytoplasm (GO:0005737), centriole (GO:0005814), cytosol (GO:0005829), microtubule cytoskeleton (GO:0015630), ciliary basal body (GO:0036064), cytoskeleton (GO:0005856), cell projection (GO:0042995)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Post-translational protein modification	1
Metabolism of proteins	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
microtubule organizing center	2
intracellular membraneless organelle	2
protein metabolic process	1
protein deglutamylation	1
carboxypeptidase activity	1
metalloexopeptidase activity	1
transition metal ion binding	1
cytoskeletal protein binding	1
exopeptidase activity	1
binding	1
hydrolase activity	1
catalytic activity, acting on a protein	1
peptidase activity	1
catalytic activity	1
cation binding	1
intracellular anatomical structure	1
cytoplasm	1
cytoskeleton	1
cilium	1

Protein interactions and networks

STRING

498 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
AGBL2	PRTN3	P15637	777
AGBL2	RARRES1	P49788	697
AGBL2	MASP2	O00187	645
AGBL2	HLA-DRB1	P01911	622
AGBL2	CRP	P02741	597
AGBL2	FLG	P20930	594
AGBL2	FLG2	Q5D862	594
AGBL2	C4A	P01028	594
AGBL2	C4A	P01028	557
AGBL2	LXN	Q9BS40	546
AGBL2	C1R	P00736	536
AGBL2	ENO1	P06733	527
AGBL2	C1S	P09871	519
AGBL2	FNBP4	Q8N3X1	516
AGBL2	CFHR3	Q02985	495

IntAct

2 interactions, top by confidence:

A	B	Type	Score
NUDT5	FLNB	psi-mi:“MI:0914”(association)	0.350

BioGRID (13): TPM2 (Affinity Capture-MS), AGBL2 (Two-hybrid), AGBL2 (Two-hybrid), AGBL2 (Affinity Capture-MS), AGBL2 (Cross-Linking-MS (XL-MS)), AGBL2 (Cross-Linking-MS (XL-MS)), AGBL2 (Affinity Capture-MS), EEA1 (Cross-Linking-MS (XL-MS)), AGBL2 (Protein-peptide), AGBL2 (Proximity Label-MS), AGBL2 (Affinity Capture-Western), AGBL2 (Affinity Capture-Western), AGBL2 (Affinity Capture-Western)

ESM2 similar proteins: A0JM98, A1L1H3, A2A5N8, A4IGY9, A7E2Z2, D3ZWK4, E1B9D8, E1C2V1, O70445, P70351, Q08BS4, Q08EN7, Q0P4M4, Q28D84, Q4V863, Q5RDS6, Q5T890, Q5TKR9, Q5U5Z8, Q5ZIX8, Q61188, Q6DJS0, Q6GQJ2, Q6IE81, Q6IE82, Q6IVY4, Q6YI93, Q6ZPI0, Q7Z2W4, Q7ZVP1, Q803A0, Q80Z32, Q86VD1, Q8BMD7, Q8BRB7, Q8BZ21, Q8C4P0, Q8CDK2, Q8CDP0, Q8N8K9

Diamond homologs: A6H8T7, A9JRL3, B2GV17, D2GXM8, E1B9D8, E1C3P4, O76373, Q09296, Q09LZ8, Q09M02, Q09M05, Q0P4M4, Q4R632, Q4U2V3, Q5U5Z8, Q5VU57, Q641K1, Q6DD21, Q8CDK2, Q8CDP0, Q8I2A6, Q8NDL9, Q8NEM8, Q96MI9, Q9UPW5, Q9VY99, Q58CX9, B0JZV4, Q68EI3, P30795, A0A096LPI5, Q8N976, Q96MD7

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

126 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	92
Likely benign	9
Benign	5

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
3392517	Single allele	Pathogenic

SpliceAI

3170 predictions. Top by Δscore:

Variant	Effect	Δscore
11:47667569:A:AC	donor_gain	1.0000
11:47667570:C:CC	donor_gain	1.0000
11:47667703:C:CT	acceptor_gain	1.0000
11:47668915:C:CT	acceptor_gain	1.0000
11:47668915:C:T	acceptor_gain	1.0000
11:47668916:A:T	acceptor_gain	1.0000
11:47677265:TGTTA:T	donor_loss	1.0000
11:47677266:GTTAC:G	donor_loss	1.0000
11:47677267:TTACC:T	donor_loss	1.0000
11:47677268:TAC:T	donor_loss	1.0000
11:47677269:A:T	donor_loss	1.0000
11:47677270:C:A	donor_loss	1.0000
11:47677309:T:TA	donor_gain	1.0000
11:47677397:GTGAA:G	acceptor_gain	1.0000
11:47677398:TGAA:T	acceptor_gain	1.0000
11:47677399:GAA:G	acceptor_gain	1.0000
11:47677401:AC:A	acceptor_loss	1.0000
11:47677402:C:CC	acceptor_gain	1.0000
11:47677404:A:C	acceptor_gain	1.0000
11:47677410:G:GC	acceptor_gain	1.0000
11:47679967:TTTTA:T	donor_loss	1.0000
11:47679968:TTTA:T	donor_loss	1.0000
11:47679969:TTAC:T	donor_loss	1.0000
11:47679970:TA:T	donor_loss	1.0000
11:47679972:C:CT	donor_loss	1.0000
11:47680070:TTACC:T	acceptor_loss	1.0000
11:47680071:TACCT:T	acceptor_loss	1.0000
11:47680072:ACC:A	acceptor_loss	1.0000
11:47680073:CCT:C	acceptor_loss	1.0000
11:47680075:T:A	acceptor_loss	1.0000

AlphaMissense

5977 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
11:47690650:A:G	W353R	0.999
11:47690650:A:T	W353R	0.999
11:47690748:A:G	F320S	0.999
11:47690797:A:G	W304R	0.999
11:47690797:A:T	W304R	0.999
11:47690141:C:A	R522S	0.998
11:47690141:C:G	R522S	0.998
11:47690142:C:A	R522M	0.998
11:47690142:C:G	R522T	0.998
11:47690181:C:A	G509V	0.998
11:47690182:C:A	G509W	0.998
11:47690423:G:C	S428R	0.998
11:47690423:G:T	S428R	0.998
11:47690425:T:G	S428R	0.998
11:47690572:A:G	W379R	0.998
11:47690572:A:T	W379R	0.998
11:47690838:A:G	L290P	0.998
11:47685980:G:C	F567L	0.997
11:47685980:G:T	F567L	0.997
11:47685982:A:G	F567L	0.997
11:47690151:T:G	D519A	0.997
11:47690177:A:C	N510K	0.997
11:47690177:A:T	N510K	0.997
11:47690181:C:T	G509E	0.997
11:47690323:G:C	H462D	0.997
11:47690328:C:A	R460I	0.997
11:47690781:A:T	V309D	0.997
11:47692121:A:G	L277P	0.997
11:47682054:T:A	K610N	0.996
11:47682054:T:G	K610N	0.996

dbSNP variants (sampled 300 via entrez): RS1000053744 (11:47661356 A>C), RS1000089109 (11:47702685 C>T), RS1000116708 (11:47694329 G>T), RS1000183748 (11:47681807 A>C), RS1000209245 (11:47665061 T>C), RS1000217006 (11:47709665 G>A), RS1000220899 (11:47661882 G>T), RS1000245055 (11:47659439 A>G), RS1000293110 (11:47661628 T>C), RS1000352185 (11:47666628 A>G), RS1000373563 (11:47715878 A>G), RS1000377301 (11:47669109 C>T), RS1000425828 (11:47715611 G>C), RS1000464813 (11:47681881 C>G,T), RS1000628437 (11:47696095 G>A)

Disease associations

OMIM: gene MIM:617345 | disease phenotypes: MIM:601495

GenCC curated gene-disease

Disease	Classification	Inheritance
epilepsy	Limited	Autosomal recessive

Mondo (2): agammaglobulinemia (MONDO:0015977), epilepsy (MONDO:0005027)

Orphanet (1): Agammaglobulinemia (Orphanet:183669)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

26 associations (top):

Study	Trait	p-value
GCST002580_1	Intraocular pressure	1.000000e-11
GCST004627_15	Lymphocyte count	8.000000e-18
GCST005232_56	Neuroticism	1.000000e-16
GCST005531_2	Multiple sclerosis	1.000000e-09
GCST005905_14	Global electrical heterogeneity phenotypes	6.000000e-09
GCST006923_11	Loneliness	1.000000e-07
GCST006924_13	Loneliness (MTAG)	1.000000e-08
GCST007094_204	Diastolic blood pressure	2.000000e-10
GCST007095_35	Systolic blood pressure	9.000000e-07
GCST007096_137	Pulse pressure	3.000000e-10
GCST007099_142	Systolic blood pressure	4.000000e-16
GCST007559_27	Sleep duration (short sleep)	4.000000e-08
GCST007709_285	General factor of neuroticism	1.000000e-10
GCST007825_4	Alzheimer’s disease or fasting glucose levels (pleiotropy)	3.000000e-16
GCST007923_30	Medication use (drugs used in diabetes)	4.000000e-08
GCST008129_74	Body mass index	1.000000e-31
GCST008522_33	Bitter alcoholic beverage consumption	5.000000e-14
GCST008876_19	Non-lobar intracerebral hemorrhage (MTAG)	8.000000e-07
GCST009217_5	Corpus callosum Mid-posterior volume	7.000000e-06
GCST010002_238	Refractive error	2.000000e-14
GCST010136_2	Fruit consumption	5.000000e-09
GCST010703_36	Brain morphology (MOSTest)	8.000000e-09
GCST011439_14	Glaucoma (primary open-angle)	3.000000e-08
GCST90002401_180	Platelet distribution width	2.000000e-18
GCST90011768_22	Glaucoma (primary open-angle)	9.000000e-09
GCST90013405_93	Liver enzyme levels (alanine transaminase)	2.000000e-11

EFO canonical traits (15, from GWAS)

EFO ID	Trait name
EFO:0004695	intraocular pressure measurement
EFO:0004587	lymphocyte count
EFO:0007660	neuroticism measurement
EFO:0004327	electrocardiography
EFO:0007865	loneliness measurement
EFO:0006336	diastolic blood pressure
EFO:0006335	systolic blood pressure
EFO:0005763	pulse pressure measurement
EFO:0009924	Drugs used in diabetes use measurement
EFO:0004340	body mass index
EFO:0010092	bitter alcoholic beverage consumption measurement
EFO:0010178	non-lobar intracerebral hemorrhage
EFO:0008111	diet measurement
EFO:0004346	neuroimaging measurement
EFO:0007984	platelet component distribution width

MeSH disease descriptors (2)

Descriptor	Name	Tree numbers
D000361	Agammaglobulinemia	C15.378.147.142; C15.604.515.032; C20.673.088
D004827	Epilepsy	C10.228.140.490

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL3886062 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

5 potent at pChembl≥5 of 5 total, top 4 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
8.31	Ki	4.89	nM	CHEMBL3917902
7.06	Ki	87	nM	CHEMBL4448221
6.76	Ki	173	nM	CHEMBL4546565
6.37	Ki	428	nM	CHEMBL4589358

CTD chemical–gene interactions

29 total (human), top 29 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, decreases expression	6
trichostatin A	decreases expression, affects cotreatment	3
Acetaminophen	decreases expression, increases expression	2
Estradiol	affects cotreatment, decreases expression	2
Phenylmercuric Acetate	affects cotreatment, decreases expression	2
Smoke	decreases expression, increases abundance, increases expression	2
aristolochic acid I	increases expression	1
FR900359	increases phosphorylation	1
methylmercuric chloride	decreases expression	1
triphenyl phosphate	affects expression	1
beta-lapachone	decreases expression	1
sodium arsenite	decreases expression	1
butyraldehyde	decreases expression	1
perfluorooctane sulfonic acid	decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
abrine	decreases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
bisphenol S	decreases expression	1
Air Pollutants	increases expression, increases abundance	1
Benzo(a)pyrene	affects methylation, decreases methylation	1
Caffeine	decreases phosphorylation	1
Cisplatin	increases expression	1
Quercetin	increases expression	1
Testosterone	decreases expression	1
Tobacco Smoke Pollution	decreases expression	1
Cyclosporine	decreases expression	1
Aflatoxin B1	decreases expression	1
Okadaic Acid	decreases expression	1
Particulate Matter	increases expression	1

ChEMBL screening assays

3 unique, capped per target: 3 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL3882385	Binding	Inhibition of recombinant N-terminal His-tagged AGBL2 (unknown origin) assessed as tyrosine release using tyrosinated C-terminal tail of tubulin as substrate in presence of hydroxycoumarin preincubated for 30 to 60 mins followed by substrat	Small molecule inhibitors of AGBL2

Clinical trials (associated diseases)

314 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00004637	PHASE4	COMPLETED	Double-Blind, Placebo-Controlled Trial of Vitamin E as Add-on Therapy for Children With Epilepsy
NCT00043914	PHASE4	COMPLETED	Measurement Of Serum Levels Of Two Antiepileptic Drugs During Conversion In Patients With Epilepsy
NCT00132223	PHASE4	UNKNOWN	Effects on the Diagnostic Accuracy of Magnetic Imaging Angiographies of the Supra-Aortic Vessels by Three Different Magnetic Resonance Contrast Agents in Patients
NCT00133081	PHASE4	UNKNOWN	Study to Improve the Treatment of Epilepsy (SITE)
NCT00137709	PHASE4	UNKNOWN	Hormone Profiles in Adults With Newly Diagnosed Epilepsy
NCT00154076	PHASE4	COMPLETED	A Multicenter Comparative Trial of Zonisamide and Topiramate as Initial Monotherapy in Untreated Epilepsies
NCT00165828	PHASE4	TERMINATED	Efficacy and Safety of an add-on Treatment With Zonisamide in Adults With Focal Epileptic Seizures With or Without Secondary Generalization
NCT00181116	PHASE4	COMPLETED	Levetiracetam for Benign Rolandic Epilepsy
NCT00207935	PHASE4	COMPLETED	Use of Sustained Release Antiepileptic Medication (Depakote® ER) for Pediatric Epilepsy in a Mental Retardation/Developmental Disorder Population
NCT00215592	PHASE4	COMPLETED	Open Label, Zonegran (Zonisamide) In Partial Onset Seizures
NCT00266604	PHASE4	COMPLETED	A Study to Evaluate the Dosing, Effectiveness and Safety of Topiramate for the Treatment of Epilepsy
NCT00288639	PHASE4	COMPLETED	Lyrica (Pregabalin) Administered as an Add-on Therapy for Partial Seizures (LEADER).
NCT00312676	PHASE4	UNKNOWN	Compare Tolerability of an Overnight Switch to Gradual Switch Between Two Different Forms of Depakote
NCT00323947	PHASE4	COMPLETED	Methylphenidate for Treating Attention Deficit Hyperactivity Disorder in Children With Both ADHD and Epilepsy
NCT00385411	PHASE4	COMPLETED	Study of Valproate in Young Patients Suffering From Epilepsy
NCT00522418	PHASE4	TERMINATED	Study Comparing Best Medical Practice With or Without VNS Therapy in Pharmacoresistant Partial Epilepsy Patients
NCT00537940	PHASE4	COMPLETED	Comparative Study Of Pregabalin And Gabapentin As Adjunctive Therapy In Subjects With Partial Seizures
NCT00552526	PHASE4	UNKNOWN	Ketogenic Diet vs.Antiepileptic Drug Treatment in Drug Resistant Epilepsy
NCT00564915	PHASE4	COMPLETED	RCT of the Efficacy of the Ketogenic Diet in the Treatment of Epilepsy
NCT00571155	PHASE4	COMPLETED	Trial of Levetiracetam in Patients With Primary Brain Tumors and Symptomatic Seizures Who Undergo Surgery
NCT00572195	PHASE4	COMPLETED	RNS® System LTT Study
NCT00610532	PHASE4	TERMINATED	Evaluating the Transporter Protein Inhibitor Probenecid In Patients With Epilepsy
NCT00630357	PHASE4	COMPLETED	Trial to Evaluate the Safety and Efficacy of Keppra After Conversion to Mono-therapy in Subjects With Partial Epilepsy
NCT00630630	PHASE4	COMPLETED	Study on Safety and Efficacy of Levetiracetam in the Adjunctive Treatment of Female Subjects With C1 Catamenial Epilepsy
NCT00630968	PHASE4	COMPLETED	S.K.A.T.E.: Safety of Keppra as Adjunctive Therapy in Epilepsy
NCT00631150	PHASE4	COMPLETED	A Phase IV-Pharmacovigilance Study of Keppra Greece - S.K.A.T.E.: Safety of Keppra as Adjunctive Therapy in Epilepsy
NCT00659958	PHASE4	COMPLETED	ZAGAL Study: Evaluating Effectiveness and Tolerability of Zonisamide as Adjunctive Therapy in Patients With Partial Onset Seizures Treated With Two Antiepileptic Drugs
NCT00713622	PHASE4	COMPLETED	Comparing The Effect On Cognition Of Adjunctive Therapy With Zonisamide Versus Sodium Valproate
NCT00807989	PHASE4	COMPLETED	The Efficacy and Safety of Low Dose Combination of LTG and VPA Compared to CBZ Monotherapy
NCT00832884	PHASE4	COMPLETED	The Safety of Intravenous Lacosamide
NCT00869622	PHASE4	COMPLETED	Antiepileptic Drugs and Osteoporotic Prevention Trial
NCT00896987	PHASE4	COMPLETED	Lamotrigine Cognitive Function Study in Adult Untreated Epilepsies
NCT00952081	PHASE4	COMPLETED	A Pilot Study to Evaluate Efficacy and Safety of Clevidipine in Neurosurgical Patients
NCT01118455	PHASE4	TERMINATED	Trial to Assess Vagus Nerve Stimulation Therapy vs. Anti-Epileptic Drug (AED) Treatment in Children With Refractory Seizures
NCT01127165	PHASE4	COMPLETED	Low and High Dose Zonisamide in Children as Monotherapy
NCT01127256	PHASE4	COMPLETED	Comparative Study of Zonisamide and Carbamazepine as an Initial Monotherapy: Efficacy and Safety Evaluation
NCT01140867	PHASE4	COMPLETED	Open-label, Multi-center Trial of Zonisamide as Adjunctive Therapy in Patients With Uncontrolled Partial Epilepsy
NCT01175954	PHASE4	COMPLETED	Cognitive and Behavioral Effects of Lacosamide
NCT01229735	PHASE4	COMPLETED	Levetiracetam Versus Topiramate as Adjunctive Therapy to Evaluate Efficacy and Safety in Subjects With Refractory Partial Onset Seizures
NCT01244724	PHASE4	TERMINATED	Lexapro for Major Depression in Patients With Epilepsy